论文部分内容阅读
随着临床综合治疗手段和方法的不断进步,对腹膜后肿瘤,尤其是复杂性腹膜后肿瘤,术前即获取穿刺组织,进行常规病理诊断,甚至分子病理学诊断的需求越来越高。在穿刺组织上,通过常规病理诊断、免疫组织化学、荧光原位杂交以及基于PCR的分子病理技术,获得肿瘤类型、分子靶点以及药物敏感性化疗靶标等信息,为腹膜后肿瘤个体化治疗提供参考,使病人更好地从综合治疗中获益,具有重要临床意义。
With the progress of clinical comprehensive treatment methods and methods, there is a growing demand for retroperitoneal tumors, especially complex retroperitoneal tumors, to obtain the puncture tissue before surgery, perform routine pathological diagnosis, and even diagnose molecular pathology. On the puncture tissue, the tumor types, molecular targets and drug-sensitive chemotherapy targets can be obtained through routine pathological diagnosis, immunohistochemistry, fluorescence in situ hybridization and PCR-based molecular pathology, providing information for personalized treatment of retroperitoneal tumors Reference, to make patients better benefit from comprehensive treatment, has important clinical significance.